Katagiri et al. [26] observed that treatment-free molecular remission achieved by combination therapy of imatinib plus IFN-α in CML with BCL2L11 (BIM) deletion polymorphism relapsed after stopping imatinib. The gene discussed is BCL2L11; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.